SNP Array NOTE: THIS IS A SAMPLE REPORT AND MAY NOT REFLECT ACTUAL PATIENT DATA. FORMAT AND/OR CONTENT MAY BE UPDATED PERIODICALLY.
|
|
- Melvyn Thompson
- 6 years ago
- Views:
Transcription
1 SAMPLE REPORT SNP Array NOTE: THIS IS A SAMPLE REPORT AND MAY NOT REFLECT ACTUAL PATIENT DATA. FORMAT AND/OR CONTENT MAY BE UPDATED PERIODICALLY. RESULTS SNP Array Copy Number Variations Result: LOSS, Pathogenic (2p16.3) Regions of Homozygosity Result: Normal Male Change Chromosome Region Min Interval Min Size (Mb) Max Size (Mb) LOSS 2p ,848,099-50,901, SNP Array Result: arr[grch37] 2p16.3( _ )x1 INTERPRETATION COPY NUMBER VARIATIONS The results of this test indicate an interstitial copy number LOSS at 2p16.3. This copy number loss is a minimum of 53 kb and results in a partial deletion of NRXN1 from exons 6 to 8 (NM_ ). Partial copy losses involving the coding regions of NRXN1 gene of variable sizes, ranging from 14 kb to 1.15 Mb, have previously been reported. Heterozygous copy losses in NRXN1 have been reported in individuals with variable neurodevelopmental phenotypes, including intellectual disability, speech delay, autism spectrum disorders, ADHD, schizophrenia, seizures, and hypotonia (Bena, 2013; Ching, 2010; Dabell, 2013; Lal, 2015, Lowther, 2016). Short stature, macrocephaly, birth defects of the brain, and cardiac defects or dysfunction have also been reported in a small number of individuals with NRXN1 copy losses (Ching, 2010; Dabell, 2013). In reported cases, NRXN1 copy losses are often inherited from a parent, who may or may not be affected (Bena, 2013) and also documented in control populations, suggesting reduced penetrance (Kirov, 2014). Based on the gene content and supporting literature, this alteration is expected to be pathogenic. Clinical correlation is recommended. Microarray parental variant study is available for the 2p16.3 copy loss at no additional charge to determine whether this alteration is inherited or de novo. REGIONS OF HOMOZYGOSITY No regions of homozygosity were detected. Neurodevelopment-Expanded testing is in progress. The results of this analysis will be reported separately. Genetic counseling is a recommended option for all patients undergoing genetic testing. Laboratory Director: Trieu Timothy D. Vo, PhD, DABMG, FACMG. CLIA# 05D Page 1 of 5
2 Please note: Any tests on hold, previously reported, and those that have been cancelled (including reflex testing steps cancelled due to a positive result in a preceding test) have not been included in this report. For additional information, please contact Ambry Genetics. REFERENCES Bena F, et al. (2013) Am J Med Genet B Neuropsychiatr Genet 162B(4): Ching MSL, et al. (2010) Am J Med Genet B Neuropsychiatr Genet 153B(4): Dabell MP, et al. (2013) Am J Med Genet 161A(4): Kirov G, et al. (2014) Biol Psychiatry 75(5): Lal D, et al. (2015) PLoS Genet 11(5): e Lowther C, et al. (2017) Genet Med 19(1): REFSEQ GENES The 2p16.3 region contains 1 gene: NRXN1 ELECTRONICALLY SIGNED BY Sample Director, on 0/00/0000 at 0:00:00 PM Laboratory Director: Trieu Timothy D. Vo, PhD, DABMG, FACMG. CLIA# 05D Page 2 of 5
3 SNP ARRAY ASSAY INFORMATION (Supplement to Test Results) General Information: Genomic imbalances are an underlying cause of congenital anomalies, developmental delay, intellectual disability, autism, dysmorphism and numerous genetic syndromes. Routine karyotype analysis can detect some common chromosomal imbalances such as aneuploidies, but cannot detect smaller DNA rearrangements under 5 Mb. Chromosomal Microarray Analysis (CMA) via Array-based Comparative Genomic Hybridization (acgh) is a technique that allows for high resolution genome-wide detection of unbalanced structural and numerical chromosomal abnormalities. In addition, SNP probes are used to detect copy-neutral chromosomal changes, such as regions of homozygosity (ROH) the pattern of which may indicate uniparental disomy (UPD) or may suggest consanguinity and identity by descent. Importantly, the level of resolution of SNP Array depends only on the size and spacing of the oligonucleotide probes on the array. Methodology: Genomic deoxyribonucleic acid (gdna) is isolated from the patient s specimen using a standardized kit, quantified, labeled and hybridized to an oligonucleotide array with more than 1.9 million copy number probes and nearly 750,000 SNP probes used for genotyping and copy number analysis. This array allows for detection of loss of copy number (deletion), gain of copy number (duplication) or regions of homozygosity which may indicate uniparental disomy. FISH confirmation analysis, if requested, will be performed by CombiMatrix Diagnostics, 310 Goddard, Suite 150, Irvine, CA Analytical Range: The Ambry CMA: SNP Microarray (Affymetrix CytoScan HD Array, Santa Clara, CA) backbone probe spacing is set at an average of 1.1 kb throughout the entire human genome and an average of 880 basepairs in intragenic regions throughout the genome. Deletions and duplications with no known or suspected clinical relevance to the indication for testing, and regions seen frequently in control populations and documented in the Database of Genomic Variants may not be reported. The array detects currently known microdeletion/duplication syndromes, uniparental disomy due to isodisomy and most disorders detected by chromosomal analysis and FISH tests. Copy number neutral regions of homozygosity (ROH) greater than 10 Mb are reported, though this threshold may vary depending on the location and gene content of the ROH region. ROH comprising 2.5% or greater of the covered genome will be reported. Expected (Normal) Value: Diagnostic: No significant copy number changes or regions of homozygosity were detected. Family History or Carrier Screen: No significant copy number changes or regions of homozygosity were detected. Result Reports: Deletions and duplications of any size covering a known disease locus may be reported if determined to have potential clinical relevance. The copy number variant (CNV) location is reported by region and location on the chromosome, and includes the min/max size (Mb) of the span of loss or gain. Genomic coordinates corresponding to the minimum size (Min size Mb/kb) represents the distance between the first deviated proximal and distal probes of the CNV. Maximum size (Max size Mb/kb) represents the distance between the first non-deviated proximal and distal probes flanking the CNV. Array nomenclature is based on the ISCN (International System for Human Cytogenetic Nomenclature) 2016 guidelines. Analysis is based on genome assembly GRCh 37/hg19. CNVs in the following classifications are always reported, and are based on the following definitions: Pathogenic: CNV with sufficient evidence to classify as pathogenic (capable of causing disease). Likely Pathogenic: CNV with strong evidence in favor of pathogenicity. Uncertain Clinical Significance: CNV with limited and/or conflicting evidence regarding pathogenicity. Medical management to be based on personal/family clinical histories, not CNV carrier status. Variant, Likely Benign (VLB): CNV of compelling size containing genes without definitive role in clinically relevant disease Recessive disease states are not routinely reported, however well characterized disorders with high carrier population frequencies and disorders with potential clinical relevance may be reported. Clinical concern for recessive disease should be communicated to the laboratory for appropriate evaluation. Additional testing may be indicated to further characterize the alteration(s) identified. Parental analyses may be indicated to determine if the alteration(s) are de novo or inherited and to further characterize the origin of the alteration(s). Resources: The following references are used in copy number variation classification when applicable for observed alterations. 1. HGMD [Internet]: Stenson PD et al. Genome Med. 2009;1(1):13 World Wide Web URL: 2. Online Mendelian Inheritance in Man, OMIM. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD), Copyright World Wide Web URL: 3. DECIPHER database [Internet]: Bragin E, et al. Nucleic Acids Res 2014:42(Database issue):d993-d1000 World Wide Web URL: Laboratory Director: Trieu Timothy D. Vo, PhD, DABMG, FACMG. CLIA# 05D Page 3 of 5
4 4. Database of Genomic Variants: MacDonald JR, et al. Nucleic Acids Res Jan;42(Database issue):d World Wide Web URL: 5. UCSC Genome Browser: Kent WJ, et al. Genome Res Jun;12(6): World Wide Web URL: 6. ClinGen. Rehm H.L, et al. N Engl J Med (23): World Wide Web URL: Disclaimer: This test was developed and its performance characteristics were determined by Ambry Genetics Corporation. It has not been cleared or approved by the US Food and Drug Administration. The FDA does not require this test to go through premarket FDA review. It should not be regarded as investigational or for research. This test should be interpreted in context with other clinical findings. The Ambry Test: SNP Array will only detect net gain or loss of genomic material and regions of homozygosity (ROH) meeting reporting criteria and therefore is not intended to analyze the following types of chromosomal aberrations: balanced translocations, Robertsonian translocations, balanced insertions, inversions, point mutations, low level mosaicism, epigenetic abnormalities, heterodisomic or mosaic UPD or any microdeletions and duplications that are under the resolution of the array or not represented on the array. A negative result from the analysis cannot rule out the possibility that a tested individual carries an aberration in the undetectable group. Although molecular tests are highly accurate, rare diagnostic errors may occur. Possible diagnostic errors include sample mix-up, technical errors, and clerical errors. This report does not represent medical advice. Any questions, suggestions, or concerns regarding interpretation of results should be forwarded to a genetic counselor, medical geneticist, or physician skilled in interpretation of the relevant medical literature. This laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing. HiddenText Laboratory Director: Trieu Timothy D. Vo, PhD, DABMG, FACMG. CLIA# 05D Page 4 of 5
5 SNP ARRAY RESULTS: arr[grch37] 2p16.3( _ )x1 Laboratory Director: Trieu Timothy D. Vo, PhD, DABMG, FACMG. CLIA# 05D Page 5 of 5
SNP Array NOTE: THIS IS A SAMPLE REPORT AND MAY NOT REFLECT ACTUAL PATIENT DATA. FORMAT AND/OR CONTENT MAY BE UPDATED PERIODICALLY.
SAMPLE REPORT SNP Array NOTE: THIS IS A SAMPLE REPORT AND MAY NOT REFLECT ACTUAL PATIENT DATA. FORMAT AND/OR CONTENT MAY BE UPDATED PERIODICALLY. RESULTS SNP Array Copy Number Variations Result: GAIN,
More informationCHROMOSOMAL MICROARRAY (CGH+SNP)
Chromosome imbalances are a significant cause of developmental delay, mental retardation, autism spectrum disorders, dysmorphic features and/or birth defects. The imbalance of genetic material may be due
More informationChallenges of CGH array testing in children with developmental delay. Dr Sally Davies 17 th September 2014
Challenges of CGH array testing in children with developmental delay Dr Sally Davies 17 th September 2014 CGH array What is CGH array? Understanding the test Benefits Results to expect Consent issues Ethical
More informationMultiple Copy Number Variations in a Patient with Developmental Delay ASCLS- March 31, 2016
Multiple Copy Number Variations in a Patient with Developmental Delay ASCLS- March 31, 2016 Marwan Tayeh, PhD, FACMG Director, MMGL Molecular Genetics Assistant Professor of Pediatrics Department of Pediatrics
More informationApplications of Chromosomal Microarray Analysis (CMA) in pre- and postnatal Diagnostic: advantages, limitations and concerns
Applications of Chromosomal Microarray Analysis (CMA) in pre- and postnatal Diagnostic: advantages, limitations and concerns جواد کریمزاد حق PhD of Medical Genetics آزمايشگاه پاتوبيولوژي و ژنتيك پارسه
More informationCURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE. Dr. Bahar Naghavi
2 CURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE Dr. Bahar Naghavi Assistant professor of Basic Science Department, Shahid Beheshti University of Medical Sciences, Tehran,Iran 3 Introduction Over 4000
More informationClinical evaluation of microarray data
Clinical evaluation of microarray data David Amor 19 th June 2011 Single base change Microarrays 3-4Mb What is a microarray? Up to 10 6 bits of Information!! Highly multiplexed FISH hybridisations. Microarray
More informationGenetic Testing for the Developmental Delay/Intellectual Disability, Autism Spectrum Disorder, and Congenital Anomalies
Genetic Testing for the Developmental Delay/Intellectual Disability, Autism Spectrum Disorder, and Congenital Anomalies Policy Number: 2.04.59 Last Review: 5/2018 Origination: 5/2015 Next Review: 5/2019
More informationSharan Goobie, MD, MSc, FRCPC
Sharan Goobie, MD, MSc, FRCPC Chromosome testing in 2014 Presenter Disclosure: Sharan Goobie has no potential for conflict of interest with this presentation Objectives Review of standard genetic investigations
More informationGenetic Testing 101: Interpreting the Chromosomes
Genetic Testing 101: Interpreting the Chromosomes Kristin Lindstrom, MD Division of Genetics and Metabolism Phoenix Children s Hospital AzAAP Pediatrics in the Red Rocks I have no disclosures for this
More informationApproach to Mental Retardation and Developmental Delay. SR Ghaffari MSc MD PhD
Approach to Mental Retardation and Developmental Delay SR Ghaffari MSc MD PhD Introduction Objectives Definition of MR and DD Classification Epidemiology (prevalence, recurrence risk, ) Etiology Importance
More informationAssociation for Molecular Pathology Promoting Clinical Practice, Basic Research, and Education in Molecular Pathology
Association for Molecular Pathology Promoting Clinical Practice, Basic Research, and Education in Molecular Pathology 9650 Rockville Pike, Bethesda, Maryland 20814 Tel: 301-634-7939 Fax: 301-634-7990 Email:
More informationPractical challenges that copy number variation and whole genome sequencing create for genetic diagnostic labs
Practical challenges that copy number variation and whole genome sequencing create for genetic diagnostic labs Joris Vermeesch, Center for Human Genetics K.U.Leuven, Belgium ESHG June 11, 2010 When and
More informationGenetic Testing for Single-Gene and Multifactorial Conditions
Clinical Appropriateness Guidelines Genetic Testing for Single-Gene and Multifactorial Conditions EFFECTIVE DECEMBER 1, 2017 Appropriate.Safe.Affordable 2017 AIM Specialty Health 2069-1217 Table of Contents
More informationCorporate Medical Policy
Corporate Medical Policy Invasive Prenatal (Fetal) Diagnostic Testing File Name: Origination: Last CAP Review: Next CAP Review: Last Review: invasive_prenatal_(fetal)_diagnostic_testing 12/2014 3/2018
More informationFaravareh Khordadpoor (PhD in molecular genetics) 1- Tehran Medical Genetics Laboratory 2- Science and research branch, Islamic Azad University
Faravareh Khordadpoor (PhD in molecular genetics) 1- Tehran Medical Genetics Laboratory 2- Science and research branch, Islamic Azad University 1395 21 مشاوره ژنتیک و نقش آن در پیش گیری از معلولیت ها 20
More informationSection: Medicine Effective Date: January15, 2016 Subsection: Pathology/Laboratory Original Policy Date: December 7, 2011 Subject:
Section: Medicine Effective Date: January15, 2016 Last Review Status/Date: December 2015 Page: 1 of 22 Microarray Analysis and Next-Generation Autism Spectrum Disorder and/or Congenital Description Chromosomal
More informationClinical Genomics. Ina E. Amarillo, PhD FACMGG
Clinical Genomics Ina E. Amarillo, PhD FACMGG Associate Medical Director, Cytogenetics Lab (CaTG), Lab and Genomic Medicine Assistant Professor, Pathology and Immunology Outline Clinical Genomics Testing
More informationNational Medical Policy
National Medical Policy Subject: Policy Number: Single Nucleotide Polymorphism (SNP) Chromosomal Microarray Analysis for Prenatal Testing and Intellectual Disability, Developmental Delay, and Multiple
More information22q11.2 DELETION SYNDROME. Anna Mª Cueto González Clinical Geneticist Programa de Medicina Molecular y Genética Hospital Vall d Hebrón (Barcelona)
22q11.2 DELETION SYNDROME Anna Mª Cueto González Clinical Geneticist Programa de Medicina Molecular y Genética Hospital Vall d Hebrón (Barcelona) Genomic disorders GENOMICS DISORDERS refers to those diseases
More informationImplementation of the DDD/ClinGen OGT (CytoSure v3) Microarray
Implementation of the DDD/ClinGen OGT (CytoSure v3) Microarray OGT UGM Birmingham 08/09/2016 Dom McMullan Birmingham Women's NHS Trust WM chromosomal microarray (CMA) testing Population of ~6 million (10%)
More informationAmerican Psychiatric Nurses Association
Francis J. McMahon International Society of Psychiatric Genetics Johns Hopkins University School of Medicine Dept. of Psychiatry Human Genetics Branch, National Institute of Mental Health* * views expressed
More informationCanadian College of Medical Geneticists (CCMG) Cytogenetics Examination. May 4, 2010
Canadian College of Medical Geneticists (CCMG) Cytogenetics Examination May 4, 2010 Examination Length = 3 hours Total Marks = 100 (7 questions) Total Pages = 8 (including cover sheet and 2 pages of prints)
More informationWhat s the Human Genome Project Got to Do with Developmental Disabilities?
What s the Human Genome Project Got to Do with Developmental Disabilities? Disclosures Neither speaker has anything to disclose. Phase Two: Interpretation Officially started in October 1990 Goals of the
More informationProtocol. Genetic Testing for Developmental Delay and Autism Spectrum Disorder
Genetic Testing for Developmental Delay and Autism Spectrum (20459, 20483, 20481) Medical Benefit Effective Date: 01/01/18 Next Review Date: 09/18 Preauthorization Yes Review Dates: 09/10, 09/11, 03/12,
More informationPrenatal Diagnosis: Are There Microarrays in Your Future?
Financial Disclosure UCSF Antepartum Intrapartum Management Course June 8 I have no financial relationship with any aspect of private industry Prenatal Diagnosis: Are There Microarrays in Your Future?
More informationSEAMLESS CGH DIAGNOSTIC TESTING
SEAMLESS CGH DIAGNOSTIC TESTING GENETISURE DX POSTNATAL ASSAY Informed decisions start with a complete microarray platform for postnatal analysis For In Vitro Diagnostic Use INTENDED USE: GenetiSure Dx
More informationGenetics and Genomics: Applications to Developmental Disability
Tuesday, 12:30 2:00, B1 Objective: Genetics and Genomics: Applications to Developmental Disability Helga Toriello 616-234-2712 toriello@msu.edu Identify advances in clinical assessment and management of
More informationChromosome Microarray Analysis (CMA)
Chromosome Microarray Analysis (CMA) Ina E. Amarillo, PhD FACMG Cytogenomics Lab (Associate Medical Director) Pathology (Assistant Professor) OUTLINE Clinical Indications for Cytogenomics Testing Cytogenomics
More informationAddressing the challenges of genomic characterization of hematologic malignancies using microarrays
Addressing the challenges of genomic characterization of hematologic malignancies using microarrays Sarah South, PhD, FACMG Medical Director, ARUP Laboratories Department of Pediatrics and Pathology University
More informationTumorNext-HRD with OvaNext: Paired Germline and Tumor Analyses of Genes Involved in
SAMPLE REPORT Ordered By Contact ID:1251298 Example, Doctor, MD MOCKORG44 (10829) 123 Somewhere LaneSuite 4 Heaven NV 78872 US Ph:123-123-1234 Fx:123-123-1223 Org ID:8141 Normal Specimen Accession #: 00-086947
More informationNo mutations were identified.
Hereditary High Cholesterol Test ORDERING PHYSICIAN PRIMARY CONTACT SPECIMEN Report date: Aug 1, 2017 Dr. Jenny Jones Sample Medical Group 123 Main St. Sample, CA Kelly Peters Sample Medical Group 123
More informationCHROMOSOME MICROARRAY TESTING
CHROMOSOME MICROARRAY TESTING UnitedHealthcare Commercial Medical Policy Policy Number: 2017T0559J Effective Date: August 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationCopy Number Variants of Uncertain Significance in Prenatal diagnosis Are the Goalposts Moving? Lisa Burvill-Holmes Bristol Genetics Laboratory
Copy Number Variants of Uncertain Significance in Prenatal diagnosis Are the Goalposts Moving? Lisa Burvill-Holmes Bristol Genetics Laboratory http://www.nbt.nhs.uk/genetics Microarray CGH in Prenatal
More informationMost severely affected will be the probe for exon 15. Please keep an eye on the D-fragments (especially the 96 nt fragment).
SALSA MLPA probemix P343-C3 Autism-1 Lot C3-1016. As compared to version C2 (lot C2-0312) five reference probes have been replaced, one reference probe added and several lengths have been adjusted. Warning:
More informationRACP Congress 2017 Genetics of Intellectual Disability and Autism: Past Present and Future 9 th May 2017
RACP Congress 2017 Genetics of Intellectual Disability and Autism: Past Present and Future 9 th May 2017 Why causation? Explanation for family Prognosis Recurrence risk and reproductive options Guide medical
More informationGenetics: More Than 23 and Me
Genetics: More Than 23 and Me Stephanie J. Offord, FNP-BC, AGN-BC, MSN Gina Lewis, CPNP-PC, MSN Suzanne Ducett, BSN, RN Interactive questions in presentation. Text NPGENETICS123 to 22333 once to join DISCLOSURE
More informationStructural Variation and Medical Genomics
Structural Variation and Medical Genomics Andrew King Department of Biomedical Informatics July 8, 2014 You already know about small scale genetic mutations Single nucleotide polymorphism (SNPs) Deletions,
More informationClinical Cytogenomics Laboratory. Laboratory. Leading diagnostics for better medicine. Beaumont
Clinical Cytogenomics Laboratory Leading diagnostics for better medicine Beaumont Laboratory Beaumont Laboratory s Clinical Cytogenomics Lab Genome decoding is essential Knowledge of variations in genome
More informationMedical Policy. MP Invasive Prenatal (Fetal) Diagnostic Testing
Medical Policy MP 2.04.116 BCBSA Ref. Policy: 2.04.116 Last Review: 04/30/2018 Effective Date: 04/30/2018 Section: Medicine Related Policies 2.04.59 Genetic Testing for Developmental Delay/Intellectual
More informationSNP Microarray. Prenatal
SNP Microarray Prenatal SNP Microarray Reveal SNP Microarray is a test that analyzes chromosomes for changes that can explain certain kinds of birth defects. This brochure is designed to answer some of
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): April 26, 2011 Most Recent Review Date (Revised): January 28, 2014 Effective Date: June 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationInvasive Prenatal (Fetal) Diagnostic Testing
Protocol Invasive Prenatal (Fetal) Diagnostic Testing (204116) Medical Benefit Effective Date: 04/01/18 Next Review Date: 01/19 Preauthorization Yes Review Dates: 01/15, 01/16, 01/17, 01/18 Preauthorization
More informationCNV Detection and Interpretation in Genomic Data
CNV Detection and Interpretation in Genomic Data Benjamin W. Darbro, M.D., Ph.D. Assistant Professor of Pediatrics Director of the Shivanand R. Patil Cytogenetics and Molecular Laboratory Overview What
More informationDr Dipti Deshmukh. Mayu Uemura. 11th September Introduction
Genetic Findings in Children with Unexplained Developmental Delay Dr Dipti Deshmukh Neurodevelopmental Consultant, St. George's Hospital, London Mayu Uemura 4th year MBBS4, St George s University of London
More informationMP Genetic Testing for Developmental Delay/Intellectual Disability, Autism Spectrum Disorder, and Congenital Anomalies
Medical Policy Genetic Testing for Developmental Delay/Intellectual Disability, Autism Spectrum Disorder, and Congenital BCBSA Ref. Policy: 2.04.59 Last Review: 10/18/2018 Effective Date: 10/18/2018 Section:
More informationIncreasing the Sensitivity of Genomic Assays Permits a Higher Resolution Study of the Human Genome. Our Current Knowledge of Genetics and Genomics
Our Current Knowledge of Genetics and Genomics Unlocking the Diagnostic Potential of Genomic Medicine The Beaumont DNA Array Experience Mark Micale, Ph.D., F.A.C.M.G. Medical Director, Clinical Cytogenomics
More informationGlobal variation in copy number in the human genome
Global variation in copy number in the human genome Redon et. al. Nature 444:444-454 (2006) 12.03.2007 Tarmo Puurand Study 270 individuals (HapMap collection) Affymetrix 500K Whole Genome TilePath (WGTP)
More informationWhole-Genome SNP Array Analysis Genomic Complexity and Clinical Relevance in Prenatal, Postnatal, and Oncology Testing
The Evolution of Cytogenetics Testing Whole-Genome SNP Array Analysis Genomic Complexity and Clinical Relevance in Prenatal, Postnatal, and Oncology Testing Mark Micale, Ph.D., F.A.C.M.G. Medical Director,
More information(2018) Keywords: Balanced rearrangement; Chromosomal microarray; genetic testing; mosaicism; UPD
American College of Medical Genetics and Genomics Yield of additional genetic testing after chromosomal microarray for diagnosis of neurodevelopmental disability and congenital anomalies: a clinical practice
More informationMEDICAL GENOMICS LABORATORY. Non-NF1 RASopathy panel by Next-Gen Sequencing and Deletion/Duplication Analysis of SPRED1 (NNP-NG)
Non-NF1 RASopathy panel by Next-Gen Sequencing and Deletion/Duplication Analysis of SPRED1 (NNP-NG) Ordering Information Acceptable specimen types: Blood (3-6ml EDTA; no time limitations associated with
More informationChapter 1 : Genetics 101
Chapter 1 : Genetics 101 Understanding the underlying concepts of human genetics and the role of genes, behavior, and the environment will be important to appropriately collecting and applying genetic
More informationGenetic Counselling in relation to genetic testing
Genetic Counselling in relation to genetic testing Dr Julie Vogt Consultant Geneticist West Midlands Regional Genetics Service September 2016 Disclosures for Research Support/P.I. Employee Consultant Major
More informationGenomic structural variation
Genomic structural variation Mario Cáceres The new genomic variation DNA sequence differs across individuals much more than researchers had suspected through structural changes A huge amount of structural
More informationGenetic Testing for Single-Gene and Multifactorial Conditions
Clinical Appropriateness Guidelines Genetic Testing for Single-Gene and Multifactorial Conditions EFFECTIVE MARCH 31, 2019 Appropriate.Safe.Affordable 2019 AIM Specialty Health 2069-0319 Table of Contents
More informationGenerating Spontaneous Copy Number Variants (CNVs) Jennifer Freeman Assistant Professor of Toxicology School of Health Sciences Purdue University
Role of Chemical lexposure in Generating Spontaneous Copy Number Variants (CNVs) Jennifer Freeman Assistant Professor of Toxicology School of Health Sciences Purdue University CNV Discovery Reference Genetic
More informationUpdating penetrance estimates for syndromes with variable phenotypic manifestation. Adele Corrigan June 27th
Updating penetrance estimates for syndromes with variable phenotypic manifestation Adele Corrigan June 27th Background Array CGH has led to increased identification of copy number variants (CNVs) Our understanding
More informationClinical Interpretation of Cancer Genomes
IGENZ Ltd, Auckland, New Zealand Clinical Interpretation of Cancer Genomes Dr Amanda Dixon-McIver www.igenz.co.nz 1992 Slovenia and Croatia gain independence USA and Russia declare the Cold War over Steffi
More informationHow many disease-causing variants in a normal person? Matthew Hurles
How many disease-causing variants in a normal person? Matthew Hurles Summary What is in a genome? What is normal? Depends on age What is a disease-causing variant? Different classes of variation Final
More informationGenetics update and implications for (General) Practice
Genetics update and implications for (General) Practice May 12 th 2018 Women s Health Symposium Clearwater Estate Dr Kate Gibson MB BCh, MRCP, FRACP Topics NZ Clinical Genetics delivery New Technologies
More informationMRC-Holland MLPA. Description version 29; 31 July 2015
SALSA MLPA probemix P081-C1/P082-C1 NF1 P081 Lot C1-0114. As compared to the previous B2 version (lot 0813 and 0912), 11 target probes are replaced or added, and 10 new reference probes are included. P082
More informationTHE PENNSYLVANIA STATE UNIVERSITY SCHREYER HONORS COLLEGE DEPARTMENT OF BIOCHEMISTRY AND MOLECULAR BIOLOGY
THE PENNSYLVANIA STATE UNIVERSITY SCHREYER HONORS COLLEGE DEPARTMENT OF BIOCHEMISTRY AND MOLECULAR BIOLOGY GENOME-WIDE MICROARRAY ANALYSIS IN A CASE-CONTROL STUDY REVEALS EVELATED LEVEL OF GLOBAL COPY
More informationMolecular and Clinical Characterization of Syndromes Associated With Intellectual Disability
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 880 Molecular and Clinical Characterization of Syndromes Associated With Intellectual Disability CHRISTIAN WENTZEL
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: April 15, 2018 Related Policies: 2.04.122 Chromosomal Microarray Analysis for the Evaluation of Pregnancy Loss 2.04.59 Genetic Testing for Developmental Delay/Intellectual
More informationNo mutations were identified.
Hereditary Heart Health Test DOB: May 25, 1977 ID: 123456 Sex: Female Requisition #: 123456 ORDERING PHYSICIAN Dr. Jenny Jones Sample Medical Group 123 Main St. Sample, CA SPECIMEN Type: Saliva Barcode:
More informationCytogenetics 101: Clinical Research and Molecular Genetic Technologies
Cytogenetics 101: Clinical Research and Molecular Genetic Technologies Topics for Today s Presentation 1 Classical vs Molecular Cytogenetics 2 What acgh? 3 What is FISH? 4 What is NGS? 5 How can these
More informationNature Genetics: doi: /ng Supplementary Figure 1. PCA for ancestry in SNV data.
Supplementary Figure 1 PCA for ancestry in SNV data. (a) EIGENSTRAT principal-component analysis (PCA) of SNV genotype data on all samples. (b) PCA of only proband SNV genotype data. (c) PCA of SNV genotype
More informationCurrent controversies in prenatal diagnosis 3: is conventional chromosome analysis necessary in the post-array CGH era?
PRENATAL DIAGNOSIS Prenat Diagn 2011; 31: 235 243. Published online 10 February 2011 in Wiley Online Library (wileyonlinelibrary.com).2722 DEBATE Current controversies in prenatal diagnosis 3: is conventional
More informationWhole Exome Sequencing (WES) Whole Exome Sequencing. What Is Whole Exome Sequencing?
Whole Exome Sequencing (WES) Procedure(s) addressed by this policy: Exome (e.g., unexplained constitutional or heritable disorder or syndrome); sequence analysis Sequence analysis, each comparator exome
More informationNEW YORK STATE DEPARTMENT OF HEALTH CLINICAL LABORATORY EVALUATION PROGRAM. Crosswalk of Proposed Revisions to Cytogenetics Standards
2014 Standard 2014 Guidance 2016 Standard 2016 Guidance Cytogenetics Standard 1 (CG S1) The laboratory shall request clinical information necessary for proper initiation of test procedures and interpretation
More informationPersonalis ACE Clinical Exome The First Test to Combine an Enhanced Clinical Exome with Genome- Scale Structural Variant Detection
Personalis ACE Clinical Exome The First Test to Combine an Enhanced Clinical Exome with Genome- Scale Structural Variant Detection Personalis, Inc. 1350 Willow Road, Suite 202, Menlo Park, California 94025
More informationInvestigating rare diseases with Agilent NGS solutions
Investigating rare diseases with Agilent NGS solutions Chitra Kotwaliwale, Ph.D. 1 Rare diseases affect 350 million people worldwide 7,000 rare diseases 80% are genetic 60 million affected in the US, Europe
More informationTalking Genomes with Your Patients. Meagan Cochran, MS, CGC Certified Genetic Counselor HudsonAlpha Institute for Biotechnology
Talking Genomes with Your Patients Meagan Cochran, MS, CGC Certified Genetic Counselor HudsonAlpha Institute for Biotechnology Objectives Review the importance of physician familiarity with genomic testing
More informationWhat is New in Genetic Testing. Steven D. Shapiro MS, DMD, MD
What is New in Genetic Testing Steven D. Shapiro MS, DMD, MD 18th Annual Primary Care Symposium Financial and Commercial Disclosure I have a no financial or commercial interest in my presentation. 2 Genetic
More informationIntroduction to genetic variation. He Zhang Bioinformatics Core Facility 6/22/2016
Introduction to genetic variation He Zhang Bioinformatics Core Facility 6/22/2016 Outline Basic concepts of genetic variation Genetic variation in human populations Variation and genetic disorders Databases
More informationPATIENT CONSENT FORM Preimplantation Genetic Screening (PGS) 24 Chromosome Aneuploidy and Translocation Screening with acgh
PREIMPLANTATION GENETIC SCREENING FOR ANEUPLOIDY SCREENING INTRODUCTION Preimplantation genetic screening (PGS) is used in conjunction with in-vitro fertilization (IVF) to screen embryos for numerical
More informationMEDICAL GENOMICS LABORATORY. Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG)
Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG) Ordering Information Acceptable specimen types: Fresh blood sample (3-6 ml EDTA; no time limitations associated with receipt)
More informationMRC-Holland MLPA. Description version 08; 30 March 2015
SALSA MLPA probemix P351-C1 / P352-D1 PKD1-PKD2 P351-C1 lot C1-0914: as compared to the previous version B2 lot B2-0511 one target probe has been removed and three reference probes have been replaced.
More informationMRC-Holland MLPA. Description version 30; 06 June 2017
SALSA MLPA probemix P081-C1/P082-C1 NF1 P081 Lot C1-0517, C1-0114. As compared to the previous B2 version (lot B2-0813, B2-0912), 11 target probes are replaced or added, and 10 new reference probes are
More informationNature Genetics: doi: /ng Supplementary Figure 1
Supplementary Figure 1 Illustrative example of ptdt using height The expected value of a child s polygenic risk score (PRS) for a trait is the average of maternal and paternal PRS values. For example,
More informationCYTOGENETICS Dr. Mary Ann Perle
CYTOGENETICS Dr. Mary Ann Perle I) Mitosis and metaphase chromosomes A) Chromosomes are most fully condensed and clearly distinguishable during mitosis. B) Mitosis (M phase) takes 1 to 2 hrs and is divided
More informationHuman Genetic Variation Copy Number Variation
The Evolution of Laboratory Prenatal Diagnosis Lawrence D. Platt, MD Professor of Obstetrics and Gynecology David Geffen School of Medicine at UCLA Center for Fetal Medicine & Women s Ultrasound Los Angeles,
More informationWelcome to the Genetic Code: An Overview of Basic Genetics. October 24, :00pm 3:00pm
Welcome to the Genetic Code: An Overview of Basic Genetics October 24, 2016 12:00pm 3:00pm Course Schedule 12:00 pm 2:00 pm Principles of Mendelian Genetics Introduction to Genetics of Complex Disease
More informationMOLECULAR DIAGNOSIS for X-LINKED INTELLECTUAL DISABILITY
MOLECULAR DIAGNOSIS for X-LINKED INTELLECTUAL DISABILITY Intellectual disability (ID) or mental retardation is characterized by significant limitations in cognitive abilities and social/behavioral adaptive
More informationMerging single gene-level CNV with sequence variant interpretation following the ACMGG/AMP sequence variant guidelines
Merging single gene-level CNV with sequence variant interpretation following the ACMGG/AMP sequence variant guidelines Tracy Brandt, Ph.D., FACMG Disclosure I am an employee of GeneDx, Inc., a wholly-owned
More informationCHROMOSOME MICROARRAY TESTING (NON-ONCOLOGY CONDITIONS)
CHROMOSOME MICROARRAY TESTING (NON-ONCOLOGY CONDITIONS) UnitedHealthcare Oxford Clinical Policy Policy Number: LABORATORY 016.12 T2 Effective Date: June 1, 2018 Table of Contents Page INSTRUCTIONS FOR
More informationStructural Chromosome Aberrations
Structural Chromosome Aberrations 2 Structural chromosome aberrations or chromosome mutations represent apart from aneuploidies the most frequent pathologic findings in applied chromosome diagnostics.
More informationChromosome microarray analysis in routine prenatal diagnosis practice: a prospective study on 3000 consecutive clinical cases
Chromosome microarray analysis in routine prenatal diagnosis practice: a prospective study on 3000 consecutive clinical cases Fiorentino F, Napoletano S, Caiazzo F, Sessa M, Bono S, Spizzichino L, Gordon
More informationResearch Article Screening of 50 Cypriot Patients with Autism Spectrum Disorders or Autistic Features Using 400K Custom Array-CGH
BioMed Volume 2013, Article ID 843027, 5 pages http://dx.doi.org/10.1155/2013/843027 Research Article Screening of 50 Cypriot Patients with Autism Spectrum Disorders or Autistic Features Using 400K Custom
More informationMLPA SAMPLES USER GUIDE
MLPA SAMPLES USER GUIDE MLPA microdeletion studies Requirements: 1-2 mls (minimum) of peripheral blood in a lithium heparin tube (green or orange top) AND 1-2 mls of peripheral blood in a EDTA tube (purple
More informationADVANCED PGT SERVICES
Genomic Prediction ADVANCED PGT SERVICES with PGT-A using SEQ is a cost-effective, rigorously validated, unambiguous, and streamlined test for aneuploidy in blastocyst biopsies, and uses state of the art
More informationNovember 9, Johns Hopkins School of Medicine, Baltimore, MD,
Fast detection of de-novo copy number variants from case-parent SNP arrays identifies a deletion on chromosome 7p14.1 associated with non-syndromic isolated cleft lip/palate Samuel G. Younkin 1, Robert
More informationGenetic Testing Methods
THE JACKSON LABORATORY Genetic Testing Methods CLINICAL AND CONTINUING EDUCATION About this resource THE GOAL The goal of this resource is to improve the primary care provider s knowledge about commonly
More informationSection: Genetic Testing Last Reviewed Date: April Policy No: 58 Effective Date: July 1, 2014
Medical Policy Manual Topic: Genetic Testing, including Chromosomal Microarray Analysis (CMA) and Next Generation Sequencing Panels, for the Genetic Evaluation of Patients with Developmental Delay/Intellectual
More informationCNNH NeuroGenomics Program Peer-to-Peer Service Consent/Information Form
CNNH NeuroGenomics Program Peer-to-Peer Service Consent/Information Form WHO WEARE The Center for Neurological and Neurodevelopmental Health (CNNH) is an innovative patient- and family-centered "Specialty
More informationUTILIZATION OF A SNP MICROARRAY FOR CHRONIC LYMPHOCYTIC LEUKEMIA: EFFICACY, INFORMATIVE FINDINGS AND PROGNOSTIC CAPABILITIES
UTILIZATION OF A SNP MICROARRAY FOR CHRONIC LYMPHOCYTIC LEUKEMIA: EFFICACY, INFORMATIVE FINDINGS AND PROGNOSTIC CAPABILITIES S Schwartz, Z Hosseini, S Schepis, P Papenhausen Laboratory Corporation of America
More informationChromosome MICROARRAY. Sharon Anderson, DNP, NNP-BC, APNG. 2.0 ANCC Contact Hours
2.0 ANCC Contact Hours Chromosome MICROARRAY Sharon Anderson, DNP, NNP-BC, APNG Abstract Over the last half century, knowledge about genetics, genetic testing, and its complexity has fl ourished. Completion
More informationSALSA MLPA probemix P169-C2 HIRSCHSPRUNG-1 Lot C As compared to version C1 (lot C1-0612), the length of one probe has been adjusted.
mix P169-C2 HIRSCHSPRUNG-1 Lot C2-0915. As compared to version C1 (lot C1-0612), the length of one has been adjusted. Hirschsprung disease (HSCR), or aganglionic megacolon, is a congenital disorder characterised
More informationNurse Prac**oner Educa*on in Developmental Disabili*es Webinar Series
Nurse Prac**oner Educa*on in Developmental Disabili*es Webinar Series Genetics and Genomics Bonnie R. Lanternier, ARNP In order for Nurse Practitioners to provide optimum care for individuals with developmental
More informationLiterature databases OMIM
Literature databases OMIM Online Mendelian Inheritance in Man OMIM OMIM is a database that catalogues all the known diseases with a genetic component, and when possible links them to the relevant genes
More information